Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is advancing the use of epigenetics to identify hidden risks for heart disease, moving beyond traditional genetic testing. The Chicago-based medical technology company has built its diagnostic platform around the science of epigenetics, which examines how lifestyle, behavior, and environmental factors influence gene expression without altering the DNA sequence itself.
Epigenetics provides a dynamic view of health, reflecting changes that occur over a person’s lifetime. While DNA remains largely static, epigenetic markers can shift in response to diet, exercise, stress, and exposure to pollutants. These markers can indicate whether certain genes are turned on or off, potentially increasing or decreasing the risk for conditions like heart disease. Cardio Diagnostics tests analyze these markers to offer a personalized risk assessment that traditional genetic tests may miss.
“Epigenetics does more than pinpoint a problem; it also provides some level of solution,” said the company’s CEO. By identifying specific epigenetic changes, the tests can guide interventions such as lifestyle modifications or targeted therapies. For example, an individual with a high-risk epigenetic profile might benefit from a tailored exercise or nutrition plan to reverse harmful changes.
The company’s approach addresses a critical gap in cardiovascular care. Many people who suffer heart attacks have no traditional risk factors like high cholesterol or a family history of heart disease. Epigenetic testing could help identify these individuals earlier, potentially preventing adverse events. Cardio Diagnostics believes its tests could become a routine part of preventive health screenings.
Investors have taken note of the potential. The company’s stock trades on Nasdaq under the ticker CDIO. For the latest updates, visit the company’s newsroom at https://ibn.fm/CDIO.
The science behind Cardio Diagnostics’ platform is supported by a growing body of research linking epigenetics to cardiovascular outcomes. Studies have shown that epigenetic changes can predict heart disease risk independently of traditional factors. By incorporating these markers, Cardio Diagnostics aims to offer a more comprehensive risk assessment.
As the field of epigenetics evolves, it promises to transform how doctors approach heart disease prevention. Rather than relying solely on static genetic information, clinicians can track dynamic changes and intervene proactively. Cardio Diagnostics is at the forefront of this shift, providing tools to decode the epigenetic contributions to heart health.
